Beijing Unicet Biotechnology

Beijing Unicet Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of innovative cell-based therapies. The company's primary focus is on Chimeric Antigen Receptor T-cell (CAR-T) therapies for hematological malignancies and Mesenchymal Stem Cell (MSC) treatments for regenerative medicine and inflammatory diseases. Unicet operates a comprehensive platform that spans from early-stage discovery and genetic engineering to large-scale GMP manufacturing. Their lead programs target well-validated antigens such as CD19 and BCMA, with several candidates currently in Phase 1 and Phase 2 clinical trials. By integrating advanced cell processing technologies with clinical expertise, Unicet aims to deliver high-quality, accessible cellular immunotherapies to patients worldwide.